News

ACR2013: As well as neonatal lupus and heart block, new research suggests that children born to women with lupus may face higher risks for autism and attention deficit hyperactivity disorder.

This 6-year-old boy presents to the ER with a 2-day history of increasing pain and swelling in his right ankle. On the day of his arrival, he also developed the rash pictured here. The patient denies any other symptoms aside from his ankle and knee pain. His chest X-ray, vital signs, complete blood count (CBC), and basic chemistry panel were normal, though urinalysis showed a trace of blood.

ACR 2013: Debates about drug costs in rheumatoid arthritis dominated discussions at ACR this year, and one session was formally billed a debate. Will less-costly triple therapy someday be mandated for early RA?

Reports in a pediatric ophthalmology journal reveal risk factors and best treatments for refractory/recurrent uveitis in JIA.

ACR2013: Apremilast, a new kind of anti-inflammatory, proved significantly better than placebo against psoriatic arthritis after 52 weeks. Adverse effects were short-lived. Results for ustekinumab also held up after a year.

Biomarkers in Vasculitis

By

An intense search is underway for better ways to support treatment decisions in the vasculitides. Here are the most promising candidate biomarkers for identifying active disease and predicting relapse.

Juvenile Chronic Arthritis

By

In a 30-year-old woman with decreased range of motion in several joints, radiographs show bony fusion, profound osteopenia, erosions and advanced arthrosis.

For the first time, the European Medicines Agency's biosimilars program has recommended approval of a monoclonal antibody. It has given thumbs-up to an alternative formulation of infliximab to treat inflammatory conditions including RA, ankylosing spondylitis, and psoriatic arthritis.

With the FDA poised to issue guidance for mobile health app designers, this review includes several well-regarded apps for rheumatoid arthritis and mentions a few newcomers.

Rheumatoid arthritis patients taking a combination of etanercept (Enbrel) and methotrexate do better, but only slightly, than those on monotherapy with the tumor necrosis factor-α inhibitor, according to a Canadian multicenter clinical trial.

Last week the major British journal published an exhaustive series of reviews on autoimmune rheumatic disease, summarized briefly here. Also new in the nonspecialty journals: Macitentan for pulmonary hypertension, small fiber neuropathy in Sjögren syndrome, and risk factors for infection with glucocorticoids.